{"id":"40bb4fd17e9af4f8cea1135c90ea31cc2e38b1ad2ea971927ce536a9f788e549","title":"The Guardian Science reports a possible lasting effect of baxdrostat","argument":"The Guardian Science reports that a small study found lower blood pressure persisted for up to two years in 14 patients who stopped taking baxdrostat after a course lasting six to 12 months. Just under a quarter came off all treatment and had normal blood pressure, but Mason Freeman says it is too early to know whether they were cured; a larger trial is under way. Baxdrostat is an aldosterone synthase inhibitor (ASI), a drug that suppresses aldosterone. The article describes primary aldosteronism as excess aldosterone from nodules or benign tumours on the adrenal glands, which raises blood pressure by prompting the kidneys to retain salt. The finding matters because, if the lasting effect is common, Freeman says treatment and diagnosis could change: patients might try an ASI first and avoid invasive diagnostic procedures and surgery if they respond. That possibility is not established by this small study. Morris Brown suspects reactive oxygen species may destroy cells that overproduce aldosterone, based partly on earlier mouse research; he says this proposed mechanism is being tested in the laboratory.","topicIds":["intelligence-and-discovery","power-and-infrastructure"],"domain":"science","claimType":"attributed reading","limits":"The finding comes from a small study of 14 patients; the article says a larger trial is under way. It is too early to say whether some patients were cured. The proposed mechanism is Brown's suspicion and is being tested in the laboratory.","speaker":{"name":"Ian Sample","roleAtSource":"Article author"},"source":{"title":"New drug could be cure for common cause of high blood pressure","publisher":"The Guardian","format":"Article","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","publishedAt":"2026-11-08T13:53:41.000Z","dateBasis":"Date stated by the publisher."},"evidence":[{"text":"The study followed 14 patients whose blood pressure improved on baxdrostat and remained lower up to two years after they stopped taking it.","excerpt":"When doctors checked the patients up to two years later, their blood pressure was still lower.","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","relationship":"Source-stated"},{"text":"Just under a quarter of the patients came off all treatment and had normal blood pressure; whether they were cured remains uncertain.","excerpt":"Just under a quarter of the patients came off all treatment and had completely normal blood pressure.","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","relationship":"Source-stated"},{"text":"Freeman says that if the effect is common and persistent, diagnosis and treatment could change, potentially allowing responders to avoid invasive procedures and surgery.","excerpt":"If this effect is common and very persistent then the approach to diagnosing and treating these patients is likely to dramatically change","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","relationship":"Source-stated"},{"text":"Brown suspects reactive oxygen species may destroy cells that overproduce aldosterone, and says the proposed mechanism is being tested.","excerpt":"Those oxygen radicals are killing the cells and they disappear,” Brown said. “That’s what I think the mechanism is and it’s testable","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","relationship":"Source-stated"}],"sourceMedia":{"status":"found","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","checkedAt":"2026-11-08T14:00:49.671Z","items":[{"type":"image","url":"https://i.guim.co.uk/img/media/fad4e33bcddae0e5dd40cd1928698dc2850b785f/443_0_6142_4912/master/6142.jpg?width=465&dpr=1&s=none&crop=none","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","attribution":"The Guardian","basis":"publisher-embed","availability":"verified","label":"A woman measuring her own blood pressure at home","verifiedAt":"2026-11-08T14:00:50.312Z"}],"note":"Media declared by the original publisher; availability checked separately from the editorial reading."},"assumptions":[],"openQuestion":{"attribution":"Open question","text":"Will the larger trial find that the lasting blood-pressure reduction is common, and can it establish whether some patients were cured?"},"whatWouldChangeView":{"attribution":"Change condition not recorded","text":""},"editorialComparisons":[],"live":{"title":"The Guardian Science reports a possible lasting effect of baxdrostat","summary":"The Guardian Science reports that a small study found lower blood pressure persisted for up to two years in 14 patients who stopped taking baxdrostat after a course lasting six to 12 months. Just under a quarter came off all treatment and had normal blood pressure, but Mason Freeman says it is too early to know whether they were cured; a larger trial is under way. Baxdrostat is an aldosterone synthase inhibitor (ASI), a drug that suppresses aldosterone. The article describes primary aldosteronism as excess aldosterone from nodules or benign tumours on the adrenal glands, which raises blood pressure by prompting the kidneys to retain salt. The finding matters because, if the lasting effect is common, Freeman says treatment and diagnosis could change: patients might try an ASI first and avoid invasive diagnostic procedures and surgery if they respond. That possibility is not established by this small study. Morris Brown suspects reactive oxygen species may destroy cells that overproduce aldosterone, based partly on earlier mouse research; he says this proposed mechanism is being tested in the laboratory.","question":"Will the larger trial find that the lasting blood-pressure reduction is common, and can it establish whether some patients were cured?","claims":[{"text":"The study followed 14 patients whose blood pressure improved on baxdrostat and remained lower up to two years after they stopped taking it.","excerpt":"When doctors checked the patients up to two years later, their blood pressure was still lower.","support":"source-stated"},{"text":"Just under a quarter of the patients came off all treatment and had normal blood pressure; whether they were cured remains uncertain.","excerpt":"Just under a quarter of the patients came off all treatment and had completely normal blood pressure.","support":"source-stated"},{"text":"Freeman says that if the effect is common and persistent, diagnosis and treatment could change, potentially allowing responders to avoid invasive procedures and surgery.","excerpt":"If this effect is common and very persistent then the approach to diagnosing and treating these patients is likely to dramatically change","support":"source-stated"},{"text":"Brown suspects reactive oxygen species may destroy cells that overproduce aldosterone, and says the proposed mechanism is being tested.","excerpt":"Those oxygen radicals are killing the cells and they disappear,” Brown said. “That’s what I think the mechanism is and it’s testable","support":"source-stated"}],"limitations":["The finding comes from a small study of 14 patients; the article says a larger trial is under way.","It is too early to say whether some patients were cured. The proposed mechanism is Brown's suspicion and is being tested in the laboratory."],"mediaId":"187b7a056722108fcd6ac3974f74c5484bd5dcd820c03e960753d20fa8ccc420","correctionReason":null,"id":"40bb4fd17e9af4f8cea1135c90ea31cc2e38b1ad2ea971927ce536a9f788e549","publicationId":"479fdd77-3905-47fb-8185-5f0ed7088978","version":1,"sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","sourceTitle":"New drug could be cure for common cause of high blood pressure","publisher":"The Guardian Science","publishedAt":"2026-11-08T13:53:41.000Z","originalPublished":{"value":"2026-11-08T13:53:41.000Z","precision":"instant","basis":"publisher_page"},"firstObservedAt":"2026-11-08T13:57:27.924Z","createdAt":"2026-11-08T14:02:14.644Z","historical":false,"entityIds":["guardian-science"],"topicIds":["intelligence-and-discovery","power-and-infrastructure"],"media":[{"id":"187b7a056722108fcd6ac3974f74c5484bd5dcd820c03e960753d20fa8ccc420","kind":"article","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","label":"Read original","provenance":"source_link","verification":{"status":"verified","checkedAt":"2026-11-08T14:00:50.312Z","method":"acquired_source","contentType":"text/html"},"recommendationReason":"Recommended by Jev for understanding this source; checked by Luna."},{"id":"02ff2176b75699ee93f18a0e39404be9954638152917041881a7fe605d109a5f","kind":"image","url":"https://i.guim.co.uk/img/media/fad4e33bcddae0e5dd40cd1928698dc2850b785f/443_0_6142_4912/master/6142.jpg?width=465&dpr=1&s=none&crop=none","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","label":"A woman measuring her own blood pressure at home","provenance":"publisher_page","verification":{"status":"verified","checkedAt":"2026-11-08T14:00:50.312Z","method":"publisher_association_and_head","contentType":"image/jpeg","cacheUntil":1794146750312},"recommendationReason":"Observed on the acquired publisher source; availability checked."}],"sourceMedia":{"status":"found","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","checkedAt":"2026-11-08T14:00:49.671Z","items":[{"type":"image","url":"https://i.guim.co.uk/img/media/fad4e33bcddae0e5dd40cd1928698dc2850b785f/443_0_6142_4912/master/6142.jpg?width=465&dpr=1&s=none&crop=none","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","attribution":"The Guardian","basis":"publisher-embed","availability":"verified","label":"A woman measuring her own blood pressure at home","verifiedAt":"2026-11-08T14:00:50.312Z"}],"note":"Media declared by the original publisher; availability checked separately from the editorial reading."},"editorialDecision":{"outcome":"accept","reasonCodes":["material_development"],"rubricVersion":"stream-admission-v5","mediaId":"187b7a056722108fcd6ac3974f74c5484bd5dcd820c03e960753d20fa8ccc420","confidence":0.56,"provider":"typesafe","model":"jev-1.13.0","inputHash":"5de6a515e5ff054ccc0d40aff5c721194b6aea6d629d87f497fe21ea48fe09a7","decidedAt":"2026-11-08T14:00:54.967Z"},"provenance":{"textHash":"c3702d24eb7746733422f3dd6461be00c185ddf1f6b3bdde33f1677e40e6033e","observationId":"b6e041b6395d57bce6909f481966ba5d7ad6e5ad60a7186834e6caf13de04dc0","retrievedAt":"2026-11-08T14:00:49.671Z","kind":"publisher-page","preparer":{"model":"gpt-6-luna","runId":"dc161f07-dc0b-4aba-8fb8-429d1312937b"},"reviewer":{"model":"gpt-6-luna","runId":"a1f93d11-8432-488c-85f9-48c7d6e36d3d"}},"audit":{"status":"passed","reviewedAt":"2026-11-08T14:02:14.644Z","model":"anthropic/claude-opus-5.5"},"sourceAttribution":{"authors":[{"name":"Ian Sample","url":null,"kind":"Person"}],"authorRole":"article-author","hosts":[],"status":"stated","authorRoster":{"truncated":false,"omitted":0,"assertionGroupsOmitted":0},"participation":[{"actor":{"name":"Ian Sample","url":null,"kind":"Person","actorId":null},"role":"author","scope":{"kind":"work-credit","locator":null},"literalCredit":"Ian Sample","status":"stated","provenance":{"basis":"article-jsonld","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","locator":"document/html[1]/head[0]/script[59]@2580[0].author"},"assertionId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6:participation:0","identity":{"version":"entity-identity-v1","status":"unresolved","actorId":null,"canonicalActorId":null,"candidateActorIds":[],"assertions":[],"sourceObservedAt":"2026-11-08T14:00:49.671Z","knowledgeAsOf":null},"sourceVersion":{"snapshotId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","contentSha256":"f8dc1a02a6f1f675a881a42c0acac7663606329ec5f02ad86bbe8851de949ebf","textHash":"c3702d24eb7746733422f3dd6461be00c185ddf1f6b3bdde33f1677e40e6033e","observedAt":"2026-11-08T14:00:49.671Z"}},{"actor":{"name":"The Guardian","url":"https://www.theguardian.com/","kind":"unknown","actorId":null},"role":"publisher","scope":{"kind":"publication","locator":null},"literalCredit":"The Guardian","status":"stated","provenance":{"basis":"article-publisher","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","locator":"document/html[1]/head[0]/script[59]@2580[0].publisher"},"assertionId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6:participation:1","identity":{"version":"entity-identity-v1","status":"unresolved","actorId":null,"canonicalActorId":null,"candidateActorIds":[],"assertions":[],"sourceObservedAt":"2026-11-08T14:00:49.671Z","knowledgeAsOf":null},"sourceVersion":{"snapshotId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","contentSha256":"f8dc1a02a6f1f675a881a42c0acac7663606329ec5f02ad86bbe8851de949ebf","textHash":"c3702d24eb7746733422f3dd6461be00c185ddf1f6b3bdde33f1677e40e6033e","observedAt":"2026-11-08T14:00:49.671Z"}}],"participationCoverage":{"total":2,"returned":2,"complete":true,"fullAssertions":"source-metadata-endpoint"},"distribution":null,"publisher":{"name":"The Guardian","url":"https://www.theguardian.com/"},"sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","snapshotId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6","contentSha256":"f8dc1a02a6f1f675a881a42c0acac7663606329ec5f02ad86bbe8851de949ebf","textHash":"c3702d24eb7746733422f3dd6461be00c185ddf1f6b3bdde33f1677e40e6033e","observedAt":"2026-11-08T14:00:49.671Z","basis":"publisher-page-metadata","sourceLinks":7,"linksTruncated":false,"metadataUrl":"/api/pipeline/stream/40bb4fd17e9af4f8cea1135c90ea31cc2e38b1ad2ea971927ce536a9f788e549/source"}},"canonicalUrl":"https://escapemeridian.com/readings/the-guardian-science-reports-a-possible-lasting-effect-of-40bb4fd1","formats":{"html":"/readings/the-guardian-science-reports-a-possible-lasting-effect-of-40bb4fd1","markdown":"/readings/the-guardian-science-reports-a-possible-lasting-effect-of-40bb4fd1.md","json":"/readings/the-guardian-science-reports-a-possible-lasting-effect-of-40bb4fd1.json"},"attribution":"Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims.","maintainedGuideLinks":[],"readerContext":{"version":"reader-context-v1","attribution":"Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.","terms":[{"id":"term-superintelligence","name":"Superintelligence","explanation":"A hypothetical AI far more capable than people across most intellectual tasks.","referenceUrl":"https://en.wikipedia.org/wiki/Superintelligence"}],"entities":[{"id":"guardian-science","name":"The Guardian Science","kind":"organization","context":"The Guardian's science feed reports research, environment, and related public disputes.","referenceUrls":["https://www.theguardian.com/science","https://www.theguardian.com/science/rss"],"path":"/entities/guardian-science","json":"/entities/guardian-science.json","markdown":"/entities/guardian-science.md"}]},"researchQuestions":[],"withdrawn":false,"references":{"schemaVersion":1,"target":{"type":"reading","id":"40bb4fd17e9af4f8cea1135c90ea31cc2e38b1ad2ea971927ce536a9f788e549","revision":"479fdd77-3905-47fb-8185-5f0ed7088978","revisionKind":"publication-id","title":"The Guardian Science reports a possible lasting effect of baxdrostat","url":"https://escapemeridian.com/readings/the-guardian-science-reports-a-possible-lasting-effect-of-40bb4fd1"},"source":{"type":"source","id":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","revision":"c3702d24eb7746733422f3dd6461be00c185ddf1f6b3bdde33f1677e40e6033e","revisionKind":"sha256-source-text","title":"New drug could be cure for common cause of high blood pressure","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat"},"status":"available","items":[],"next":null,"scope":"Explicit citations in public readings and public file attachments to this reading. Shared topics are not citations. Other artifact types need an explicit reference adapter."},"revisions":[{"id":"40bb4fd17e9af4f8cea1135c90ea31cc2e38b1ad2ea971927ce536a9f788e549","title":"The Guardian Science reports a possible lasting effect of baxdrostat","argument":"The Guardian Science reports that a small study found lower blood pressure persisted for up to two years in 14 patients who stopped taking baxdrostat after a course lasting six to 12 months. Just under a quarter came off all treatment and had normal blood pressure, but Mason Freeman says it is too early to know whether they were cured; a larger trial is under way. Baxdrostat is an aldosterone synthase inhibitor (ASI), a drug that suppresses aldosterone. The article describes primary aldosteronism as excess aldosterone from nodules or benign tumours on the adrenal glands, which raises blood pressure by prompting the kidneys to retain salt. The finding matters because, if the lasting effect is common, Freeman says treatment and diagnosis could change: patients might try an ASI first and avoid invasive diagnostic procedures and surgery if they respond. That possibility is not established by this small study. Morris Brown suspects reactive oxygen species may destroy cells that overproduce aldosterone, based partly on earlier mouse research; he says this proposed mechanism is being tested in the laboratory.","topicIds":["intelligence-and-discovery","power-and-infrastructure"],"domain":"science","claimType":"attributed reading","limits":"The finding comes from a small study of 14 patients; the article says a larger trial is under way. It is too early to say whether some patients were cured. The proposed mechanism is Brown's suspicion and is being tested in the laboratory.","speaker":{"name":"Ian Sample","roleAtSource":"Article author"},"source":{"title":"New drug could be cure for common cause of high blood pressure","publisher":"The Guardian","format":"Article","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","publishedAt":"2026-11-08T13:53:41.000Z","dateBasis":"Date stated by the publisher."},"evidence":[{"text":"The study followed 14 patients whose blood pressure improved on baxdrostat and remained lower up to two years after they stopped taking it.","excerpt":"When doctors checked the patients up to two years later, their blood pressure was still lower.","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","relationship":"Source-stated"},{"text":"Just under a quarter of the patients came off all treatment and had normal blood pressure; whether they were cured remains uncertain.","excerpt":"Just under a quarter of the patients came off all treatment and had completely normal blood pressure.","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","relationship":"Source-stated"},{"text":"Freeman says that if the effect is common and persistent, diagnosis and treatment could change, potentially allowing responders to avoid invasive procedures and surgery.","excerpt":"If this effect is common and very persistent then the approach to diagnosing and treating these patients is likely to dramatically change","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","relationship":"Source-stated"},{"text":"Brown suspects reactive oxygen species may destroy cells that overproduce aldosterone, and says the proposed mechanism is being tested.","excerpt":"Those oxygen radicals are killing the cells and they disappear,” Brown said. “That’s what I think the mechanism is and it’s testable","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","relationship":"Source-stated"}],"sourceMedia":{"status":"found","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","checkedAt":"2026-11-08T14:00:49.671Z","items":[{"type":"image","url":"https://i.guim.co.uk/img/media/fad4e33bcddae0e5dd40cd1928698dc2850b785f/443_0_6142_4912/master/6142.jpg?width=465&dpr=1&s=none&crop=none","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","attribution":"The Guardian","basis":"publisher-embed","availability":"verified","label":"A woman measuring her own blood pressure at home","verifiedAt":"2026-11-08T14:00:50.312Z"}],"note":"Media declared by the original publisher; availability checked separately from the editorial reading."},"assumptions":[],"openQuestion":{"attribution":"Open question","text":"Will the larger trial find that the lasting blood-pressure reduction is common, and can it establish whether some patients were cured?"},"whatWouldChangeView":{"attribution":"Change condition not recorded","text":""},"editorialComparisons":[],"live":{"title":"The Guardian Science reports a possible lasting effect of baxdrostat","summary":"The Guardian Science reports that a small study found lower blood pressure persisted for up to two years in 14 patients who stopped taking baxdrostat after a course lasting six to 12 months. Just under a quarter came off all treatment and had normal blood pressure, but Mason Freeman says it is too early to know whether they were cured; a larger trial is under way. Baxdrostat is an aldosterone synthase inhibitor (ASI), a drug that suppresses aldosterone. The article describes primary aldosteronism as excess aldosterone from nodules or benign tumours on the adrenal glands, which raises blood pressure by prompting the kidneys to retain salt. The finding matters because, if the lasting effect is common, Freeman says treatment and diagnosis could change: patients might try an ASI first and avoid invasive diagnostic procedures and surgery if they respond. That possibility is not established by this small study. Morris Brown suspects reactive oxygen species may destroy cells that overproduce aldosterone, based partly on earlier mouse research; he says this proposed mechanism is being tested in the laboratory.","question":"Will the larger trial find that the lasting blood-pressure reduction is common, and can it establish whether some patients were cured?","claims":[{"text":"The study followed 14 patients whose blood pressure improved on baxdrostat and remained lower up to two years after they stopped taking it.","excerpt":"When doctors checked the patients up to two years later, their blood pressure was still lower.","support":"source-stated"},{"text":"Just under a quarter of the patients came off all treatment and had normal blood pressure; whether they were cured remains uncertain.","excerpt":"Just under a quarter of the patients came off all treatment and had completely normal blood pressure.","support":"source-stated"},{"text":"Freeman says that if the effect is common and persistent, diagnosis and treatment could change, potentially allowing responders to avoid invasive procedures and surgery.","excerpt":"If this effect is common and very persistent then the approach to diagnosing and treating these patients is likely to dramatically change","support":"source-stated"},{"text":"Brown suspects reactive oxygen species may destroy cells that overproduce aldosterone, and says the proposed mechanism is being tested.","excerpt":"Those oxygen radicals are killing the cells and they disappear,” Brown said. “That’s what I think the mechanism is and it’s testable","support":"source-stated"}],"limitations":["The finding comes from a small study of 14 patients; the article says a larger trial is under way.","It is too early to say whether some patients were cured. The proposed mechanism is Brown's suspicion and is being tested in the laboratory."],"mediaId":"187b7a056722108fcd6ac3974f74c5484bd5dcd820c03e960753d20fa8ccc420","correctionReason":null,"id":"40bb4fd17e9af4f8cea1135c90ea31cc2e38b1ad2ea971927ce536a9f788e549","publicationId":"479fdd77-3905-47fb-8185-5f0ed7088978","version":1,"sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","sourceTitle":"New drug could be cure for common cause of high blood pressure","publisher":"The Guardian Science","publishedAt":"2026-11-08T13:53:41.000Z","originalPublished":{"value":"2026-11-08T13:53:41.000Z","precision":"instant","basis":"publisher_page"},"firstObservedAt":"2026-11-08T13:57:27.924Z","createdAt":"2026-11-08T14:02:14.644Z","historical":false,"entityIds":["guardian-science"],"topicIds":["intelligence-and-discovery","power-and-infrastructure"],"media":[{"id":"187b7a056722108fcd6ac3974f74c5484bd5dcd820c03e960753d20fa8ccc420","kind":"article","url":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","label":"Read original","provenance":"source_link","verification":{"status":"verified","checkedAt":"2026-11-08T14:00:50.312Z","method":"acquired_source","contentType":"text/html"},"recommendationReason":"Recommended by Jev for understanding this source; checked by Luna."},{"id":"02ff2176b75699ee93f18a0e39404be9954638152917041881a7fe605d109a5f","kind":"image","url":"https://i.guim.co.uk/img/media/fad4e33bcddae0e5dd40cd1928698dc2850b785f/443_0_6142_4912/master/6142.jpg?width=465&dpr=1&s=none&crop=none","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","label":"A woman measuring her own blood pressure at home","provenance":"publisher_page","verification":{"status":"verified","checkedAt":"2026-11-08T14:00:50.312Z","method":"publisher_association_and_head","contentType":"image/jpeg","cacheUntil":1794146750312},"recommendationReason":"Observed on the acquired publisher source; availability checked."}],"sourceMedia":{"status":"found","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","checkedAt":"2026-11-08T14:00:49.671Z","items":[{"type":"image","url":"https://i.guim.co.uk/img/media/fad4e33bcddae0e5dd40cd1928698dc2850b785f/443_0_6142_4912/master/6142.jpg?width=465&dpr=1&s=none&crop=none","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","attribution":"The Guardian","basis":"publisher-embed","availability":"verified","label":"A woman measuring her own blood pressure at home","verifiedAt":"2026-11-08T14:00:50.312Z"}],"note":"Media declared by the original publisher; availability checked separately from the editorial reading."},"editorialDecision":{"outcome":"accept","reasonCodes":["material_development"],"rubricVersion":"stream-admission-v5","mediaId":"187b7a056722108fcd6ac3974f74c5484bd5dcd820c03e960753d20fa8ccc420","confidence":0.56,"provider":"typesafe","model":"jev-1.13.0","inputHash":"5de6a515e5ff054ccc0d40aff5c721194b6aea6d629d87f497fe21ea48fe09a7","decidedAt":"2026-11-08T14:00:54.967Z"},"provenance":{"textHash":"c3702d24eb7746733422f3dd6461be00c185ddf1f6b3bdde33f1677e40e6033e","observationId":"b6e041b6395d57bce6909f481966ba5d7ad6e5ad60a7186834e6caf13de04dc0","retrievedAt":"2026-11-08T14:00:49.671Z","kind":"publisher-page","preparer":{"model":"gpt-6-luna","runId":"dc161f07-dc0b-4aba-8fb8-429d1312937b"},"reviewer":{"model":"gpt-6-luna","runId":"a1f93d11-8432-488c-85f9-48c7d6e36d3d"}},"audit":{"status":"passed","reviewedAt":"2026-11-08T14:02:14.644Z","model":"anthropic/claude-opus-5.5"},"sourceAttribution":{"authors":[{"name":"Ian Sample","url":null,"kind":"Person"}],"authorRole":"article-author","hosts":[],"status":"stated","authorRoster":{"truncated":false,"omitted":0,"assertionGroupsOmitted":0},"participation":[{"actor":{"name":"Ian Sample","url":null,"kind":"Person","actorId":null},"role":"author","scope":{"kind":"work-credit","locator":null},"literalCredit":"Ian Sample","status":"stated","provenance":{"basis":"article-jsonld","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","locator":"document/html[1]/head[0]/script[59]@2580[0].author"},"assertionId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6:participation:0","identity":{"version":"entity-identity-v1","status":"unresolved","actorId":null,"canonicalActorId":null,"candidateActorIds":[],"assertions":[],"sourceObservedAt":"2026-11-08T14:00:49.671Z","knowledgeAsOf":null},"sourceVersion":{"snapshotId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","contentSha256":"f8dc1a02a6f1f675a881a42c0acac7663606329ec5f02ad86bbe8851de949ebf","textHash":"c3702d24eb7746733422f3dd6461be00c185ddf1f6b3bdde33f1677e40e6033e","observedAt":"2026-11-08T14:00:49.671Z"}},{"actor":{"name":"The Guardian","url":"https://www.theguardian.com/","kind":"unknown","actorId":null},"role":"publisher","scope":{"kind":"publication","locator":null},"literalCredit":"The Guardian","status":"stated","provenance":{"basis":"article-publisher","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","locator":"document/html[1]/head[0]/script[59]@2580[0].publisher"},"assertionId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6:participation:1","identity":{"version":"entity-identity-v1","status":"unresolved","actorId":null,"canonicalActorId":null,"candidateActorIds":[],"assertions":[],"sourceObservedAt":"2026-11-08T14:00:49.671Z","knowledgeAsOf":null},"sourceVersion":{"snapshotId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6","sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","contentSha256":"f8dc1a02a6f1f675a881a42c0acac7663606329ec5f02ad86bbe8851de949ebf","textHash":"c3702d24eb7746733422f3dd6461be00c185ddf1f6b3bdde33f1677e40e6033e","observedAt":"2026-11-08T14:00:49.671Z"}}],"participationCoverage":{"total":2,"returned":2,"complete":true,"fullAssertions":"source-metadata-endpoint"},"distribution":null,"publisher":{"name":"The Guardian","url":"https://www.theguardian.com/"},"sourceUrl":"https://www.theguardian.com/society/2026/nov/08/new-drug-high-blood-pressure-baxdrostat","snapshotId":"f69b7db9a08e270d77d2c48368e60ea28a6ea7eb760166c81ffd2b7cb181c8b6","contentSha256":"f8dc1a02a6f1f675a881a42c0acac7663606329ec5f02ad86bbe8851de949ebf","textHash":"c3702d24eb7746733422f3dd6461be00c185ddf1f6b3bdde33f1677e40e6033e","observedAt":"2026-11-08T14:00:49.671Z","basis":"publisher-page-metadata","sourceLinks":7,"linksTruncated":false,"metadataUrl":"/api/pipeline/stream/40bb4fd17e9af4f8cea1135c90ea31cc2e38b1ad2ea971927ce536a9f788e549/source"}}}],"audits":[{"publicationId":"479fdd77-3905-47fb-8185-5f0ed7088978","verdict":"passed","findings":[{"dimension":"attribution","status":"pass","explanation":"The reading attributes the report to The Guardian Science. It assigns the cure caution and the diagnosis/treatment scenario to Mason Freeman, and the reactive-oxygen-species mechanism to Morris Brown. Each matches the article. The 'just under a quarter' figure is Brown's quoted statement, and the reading presents it inside the Guardian's report, which is acceptable.","excerpt":"Mason Freeman, a professor of medicine at Harvard University, who was involved in the work, said it was too early to say if some of the patients were cured"},{"dimension":"summary","status":"pass","explanation":"The reading explains baxdrostat, ASI, aldosterone and primary aldosteronism in plain language, and it keeps the small sample size and the larger trial. One smaller loss of force: Freeman said the approach is 'likely to dramatically change', but the reading says it 'could change'. The smallest repair is to quote his phrase directly. The conditional framing is still preserved, so meaning is not materially distorted. The question follows directly from the evidence.","excerpt":"If this effect is common and very persistent then the approach to diagnosing and treating these patients is likely to dramatically change"},{"dimension":"date","status":"pass","explanation":"The originalPublished date, 2026-11-08T13:53:41Z, comes from the publisher page. It matches the URL path, which is dated 2026/nov/08, and the feed timestamp. No earlier first publication is indicated.","excerpt":null},{"dimension":"support","status":"pass","explanation":"The claims are grounded in the text: 14 patients, a course of six to 12 months, lower blood pressure up to two years later, just under a quarter off all treatment, a larger trial under way, and a mechanism being tested in the laboratory. The reading frames the possible benefit (avoiding invasive procedures and surgery) as Freeman's conditional scenario rather than an established fact. The word 'partly' in 'based partly on earlier mouse research' is a slight hedge, but it is harmless.","excerpt":"a larger trial was under way to find out"},{"dimension":"media","status":"pass","explanation":"The selected media is the verified direct link to the original Guardian article, which is the most direct way to reach the source.","excerpt":null}],"createdAt":"2026-11-08T14:02:14.644Z","model":"anthropic/claude-opus-5.5"}],"correctionUrl":"https://escapemeridian.com/corrections/"}